Edgars Mamis, Charlotte Duchemin, Valentina Berlin, Cyril Bernerd, Mathieu Bovigny, Eric Chevallay, Bernard Crepieux, Vadim Maratovich Gadelshin, Reinhard Heinke, Ronaldo Mendez Hernandez, Jake David Johnson, Patrīcija Kalniņa, Alexandros Koliatos, Laura Lambert, Ralf Erik Rossel, Sebastian Rothe, Julien Thiboud, Felix Weber, Klaus Wendt, Rudolfs Jānis Zabolockis, Elīna Pajuste, Thierry Stora
The radionuclides 43 Sc, 44g/mSc, and 47 Sc can be produced cost-effectively in sufficient yield for medical research and applications by irradiating natTi and natV target materials with protons. Maximizing the production yield of the therapeutic 47 Sc in the highest cross section energy range of 24-70 MeV results in the co-production of long-lived, high-γ-ray-energy 46 Sc and 48 Sc contaminants if one does not use enriched target materials. Mass separation can be used to obtain high molar activity and isotopically pure Sc radionuclides from natural target materials; however, suitable operational conditions to obtain relevant activity released from irradiated natTi and natV have not yet been established at CERN-MEDICIS and ISOLDE...
March 18, 2024: Pharmaceuticals